Xcout IntelViAqua Therapeutics
ViAqua Therapeutics is a Haifa-based biotechnology company focused on aquaculture health management. The firm develops affordable, specific, and effective oral health treatments to combat viral and bacterial diseases in shrimp and other aquatic species.
Subscribe to see ViAqua Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ViAqua Therapeutics at a glance
ViAqua Therapeutics is a biotechnology company headquartered in Israel, founded in 2014. It has raised at least $12.6M across the 2 funding rounds on record. Its most recent funding round raised $8.3M in September 2023. Xcout tracks 6 named people at ViAqua Therapeutics, including Shai Ufaz (CEO & Co-Founder | Molecular biology).
ViAqua Therapeutics leadership
- Shai UfazCEO & Co-Founder | Molecular biology
- Shai EinbinderCo-Founder | Marine biology
- Elad ZoharVP Business Development
- Rita KanteevDirector of R&D | Chemistry
- Ori KoshetOperations Manager | Formulation
- Chris BeattieActive Director of ViAqua Therapeutics | Chief Scientific Officer for AquaBounty & Champion of Innovation
ViAqua Therapeutics funding rounds
At least $12.6M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $8.3M | 7 named | |
| — | $4.3M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
ViAqua Therapeutics competitors
A few of ViAqua Therapeutics's closest competitors — see the full list of competitors and alternatives →
Okapi Sciences was a Belgian biotechnology company focused on discovering and developing antiviral medicines, particularly for veterinary applications and companion animals. It served the animal-health pharmaceutical market by developing treatments for viral diseases.
ViroVet is a biopharmaceutical company headquartered in Leuven, Belgium, established in 2015. The company focuses on addressing the significant threat of viral diseases.
Loyal is a biotechnology company developing longevity medications designed to extend the healthspan and lifespan of dogs by targeting the underlying biological processes of aging. The company provides veterinary professionals with clinical resources, education, and trial opportunities while offering dog owners information on senior canine care and aging.
ASTRA Therapeutics is a biotechnology and drug design company focused on animal health and anti-parasitic drug discovery. Located at the Swiss Innovation Park Innovaare in Villigen, Switzerland, the company leverages atomic resolution to craft next-generation small-molecule treatments against parasitic diseases.
ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufacturers producing goods for animal health, human consumption, dietary supplements, and medical foods. The company operates at the intersection of biotechnology and agricultural technology, boasting a comprehensive intellectual property portfolio. This includes distinct algal and bacterial strains, advanced biologically active molecules and complexes, innovative production and cultivation techniques, and various inventions, some patented and others pending approval, all geared towards improving human and animal well-being. Its product applications are broad, addressing areas such as promoting gut health in poultry, combating bovine mastitis, improving joint function in canines, modulating the human immune system, providing algal biomass for direct human consumption, and offering biomass-based solutions for skin care and anti-aging. Founded originally as Health Enhancement Products, Inc., the company officially rebranded to ZIVO Bioscience, Inc. in October 2014. Its corporate operations are based in Bloomfield Hills, Michigan.
ELIAS Animal Health is a medical biotechnology company focused on advancing a pipeline of immunotherapies, including a unique treatment protocol and adoptive cell therapy that vaccinates companion animals using their own cancer cells.
Get ViAqua Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about ViAqua Therapeutics? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ViAqua Therapeutics in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access